Does Aetna (CVS Health) Cover Losartan?

How Aetna (CVS Health) Formularies Categorize Losartan

Losartan potassium is a generic angiotensin II receptor blocker (ARB) approved by the FDA for hypertension, for slowing kidney disease progression in patients with type 2 diabetes and diabetic nephropathy, and as an option in heart failure with reduced ejection fraction when an ACE inhibitor cannot be tolerated. The FDA prescribing information describes these approved indications and the drug's pharmacology. Because generic losartan has been available since the patent on brand-name Cozaar expired around 2010, most Aetna plan designs place it on a preferred generic tier rather than treating it as a specialty or non-preferred product.

Exact tier and copay vary by the specific plan. On many Aetna commercial PPO products, losartan sits at Tier 1 with a low copay; some Aetna HMO products or high-deductible health plans place it at Tier 2 with a higher one. Aetna Medicare Advantage and Part D plans use CMS-defined tiering and cost-sharing rules that differ from commercial products, so Medicare beneficiaries should pull the Evidence of Coverage document for their specific plan rather than assume commercial pricing applies.

The only reliable way to know your tier, copay, and any prior authorization or step therapy flag is to look up losartan by name and strength on the Aetna member portal (aetna.com) or the CVS Caremark member site if that entity administers your pharmacy benefit, using your current plan year, since tier assignments can change each January.

Prior Authorization Criteria for Losartan on Aetna Plans

Most Aetna commercial plans do not require prior authorization (PA) for losartan prescribed for uncomplicated hypertension. PA is more likely to apply when the prescribing indication is diabetic nephropathy or heart failure, or when the dose or combination falls outside typical use.

For diabetic nephropathy, PA documentation commonly requested includes:

• A confirmed diagnosis of type 2 diabetes mellitus
• Evidence of reduced kidney function or elevated urine albumin-to-creatinine ratio (UACR), sometimes required on two measurements taken weeks apart
• A note that the prescriber reviewed renal function and potassium level within the past several months
• A reason for choosing an ARB over an ACE inhibitor, most often a history of ACE-inhibitor-induced cough, a well-documented side effect of that drug class

The clinical basis Aetna's own policy documents most often reference for the nephropathy indication is the RENAAL trial, which enrolled 1,513 patients with type 2 diabetes and nephropathy and found that losartan 50 to 100 mg daily reduced the composite outcome of doubling of serum creatinine, end-stage renal disease, or death by 16 percent compared with placebo (P<0.001). This is the primary trial supporting the nephropathy indication.

PA requests are generally submitted by the prescribing physician through Aetna's provider portal or by fax to the CVS Caremark PA unit. Plans differ in their stated turnaround commitments for routine versus urgent requests; if timing matters, ask Aetna or CVS Caremark directly what their current service-level target is rather than relying on a fixed number, since this is not standardized across all plans.

Step Therapy Requirements: What Aetna May Ask You to Try First

Step therapy requires a patient to try and fail one or more alternative drugs before the plan approves the requested medication. Aetna's step therapy rules for losartan are plan-specific, but a pattern seen in some commercial designs looks like this:

Step 1. A thiazide diuretic (commonly hydrochlorothiazide or chlorthalidone) tried for a defined period, often around 30 days.

Step 2. An ACE inhibitor (commonly lisinopril or enalapril) tried for a similar period, unless a documented contraindication or intolerance exists.

Only after documented failure, contraindication, or intolerance of the required step agents will many plans release the hold on losartan. Documented exemptions typically include bilateral renal artery stenosis, prior angioedema with an ACE inhibitor, or hyperkalemia on a diuretic. The prescriber needs to state these in the exemption request, and most states now have step therapy reform laws that require insurers to respond to a documented clinical-necessity exception request within a defined, short window, commonly 72 hours, though the exact deadline depends on your state's law.

Separately, the LIFE trial (N=9,193) compared losartan with atenolol in hypertensive patients with left ventricular hypertrophy and found a 13 percent relative risk reduction in the composite of cardiovascular death, stroke, or myocardial infarction favoring losartan (P=0.021), with a larger reduction in stroke specifically. This outcome data is sometimes cited in exception requests as supporting evidence for losartan's cardiovascular benefit, independent of the step therapy sequence itself.

Aetna Losartan Coverage Decision Path

A short sequence to work through before assuming losartan will be denied, delayed, or expensive:

1. Check the indication. For uncomplicated hypertension, most Aetna commercial plans require no PA and losartan fills like any other generic. If the indication is diabetic nephropathy or heart failure, expect a documentation request and gather labs before the prescription is sent.
2. Look up your specific plan's tier and flags before assuming a price or requirement. Formulary placement, copay amount, and whether PA or step therapy applies differ by plan design, not by the drug. A five-minute portal check avoids a surprise at the pharmacy counter.
3. If step therapy applies, check for a documented exemption first. Prior treatment failure, a contraindication (ACE-inhibitor angioedema, bilateral renal artery stenosis, hyperkalemia on a diuretic) or intolerance can bypass the requirement entirely if your prescriber documents it at the time of the initial request, rather than after a denial.
4. If denied, get the written denial before doing anything else. It states the specific criteria applied, which determines what the appeal packet needs to contain.
5. Decide whether to appeal, pay cash, or both simultaneously. Generic losartan's low cash price (roughly $10 to $18 per month) makes it reasonable to fill it out of pocket while an appeal is pending rather than pause an antihypertensive medication, which carries its own risk.
6. Escalate in order: Level 1 internal appeal, then external independent review, and a state insurance commissioner complaint if needed. Each step has its own deadline; missing the window for one forfeits it.

Appealing an Aetna Denial of Losartan

A denial letter from Aetna must state the specific reason for denial, the clinical criteria applied, and appeal instructions. Under the ACA, insurers must acknowledge an internal appeal within a short window and issue a non-urgent decision within 30 days, or within 72 hours for urgent cases.

Level 1 Internal Appeal. The prescribing physician submits a written appeal packet: a cover letter with clinical rationale, relevant lab results, applicable trial or guideline references, office notes, and the patient's prior medication history.

Guideline support is also useful here. The 2022 AHA/ACC/HFSA heart failure guideline supports ARB use in patients with heart failure with reduced ejection fraction who cannot tolerate an ACE inhibitor because of cough or angioedema, and gives that use its highest strength of recommendation. Confirm the exact guideline wording against the source document before quoting it directly in an appeal letter.

Level 2 External Independent Review. If the internal appeal is denied, Aetna must offer review by an independent, accredited review organization (IRO), and that decision is binding on Aetna under most state laws. Overturn rates for external review vary by state and by claim type; we could not verify a reliable single figure for medication-specific denials, so treat any specific percentage you see elsewhere with caution and check your state insurance department's published data if that number matters to your decision.

State Insurance Commissioner Complaint. Filing a complaint with your state's insurance commissioner alongside the Level 2 review costs nothing, takes a short time online, and creates a paper trail that can help.

Documents to prepare for any appeal:

• The denial letter, citing the specific denial code and criteria language
• A signed prescriber attestation letter on office letterhead
• Relevant labs (basic metabolic panel, UACR, HbA1c if diabetic nephropathy is the indication)
• Prior drug trial records if step therapy is the basis for denial
• Relevant guideline excerpts, verified against the primary source before inclusion

The ADA's Standards of Care state that for people with type 2 diabetes, hypertension, and diabetic kidney disease, an ACE inhibitor or ARB at the maximum tolerated dose is recommended, a Grade A recommendation. Confirm the exact current wording against the ADA Standards of Care before quoting it in an appeal, since guideline language is updated annually.

What Losartan Costs Without Aetna Coverage

If a claim is denied and the medication is needed right away, cash-pay pricing for generic losartan is genuinely low. A 30-count supply of the 50 mg tablet commonly runs in the range of $10 to $14 per month with a CVS Health Savings Program or GoodRx-type discount card; the 100 mg tablet runs somewhat higher, often in the $12 to $18 range. Prices vary by pharmacy and by which discount program is used, so it is worth comparing before filling.

Brand-name Cozaar carries a list price near $80 per month and is rarely covered at a preferred tier; most Aetna formularies either exclude it or place it on a high, non-preferred tier, which makes the generic the practical default in nearly every case.

We could not verify current manufacturer patient assistance program details for Cozaar as part of this draft. If cost is a barrier, ask your pharmacist or prescriber's office directly about current manufacturer or state pharmaceutical assistance program options, since eligibility rules and program availability change and typically do not apply while active insurance coverage for the drug is in force.

Clinical Background: Why Losartan Is Prescribed and Why Coverage Matters

Losartan blocks the angiotensin II type 1 (AT1) receptor, reducing vasoconstriction and aldosterone secretion. The FDA label describes its pharmacodynamic profile and approved dosing. Three indications account for most prescriptions, and each has a distinct evidence base relevant to a coverage argument:

Hypertension. ARBs are recommended as first-line or acceptable first-line agents in current hypertension guidelines, including in patients with compelling indications such as chronic kidney disease, diabetes, or left ventricular hypertrophy. The 2017 ACC/AHA hypertension guideline addresses ARB positioning in detail. This broad support is a large part of why Aetna rarely denies losartan for uncomplicated hypertension.

Diabetic nephropathy. The RENAAL trial remains the primary evidence: in 1,513 patients with type 2 diabetes and nephropathy followed for a mean of 3.4 years, losartan 50 to 100 mg daily reduced the composite renal outcome (doubling of creatinine, end-stage renal disease, or death) by 16 percent (P<0.001) and reduced end-stage renal disease alone by 28 percent (P=0.002). These are the specific figures worth citing in a PA request. Current ADA guidance also supports ACE inhibitor or ARB use at maximum tolerated dose in this population. See the ADA Standards of Care for current guideline language.

Heart failure with reduced ejection fraction. The ELITE II trial (N=3,152) compared losartan 50 mg with captopril in elderly heart failure patients and found no significant difference in all-cause mortality (P=0.16), but losartan was significantly better tolerated, with fewer discontinuations from adverse effects. This tolerability profile underlies its role as an alternative when an ACE inhibitor is not tolerated.

Practical Steps to Get Losartan Covered Through Aetna

Step 1. Confirm your plan formulary. Log in to aetna.com or the CVS Caremark member site, search "losartan potassium," and note the tier and any PA or step therapy flag on your specific plan. Save a screenshot with the date.

Step 2. Ask the prescriber to submit PA at the time of prescribing, if the indication requires it, so there is no gap in therapy while waiting on a decision.

Step 3. Gather labs before the PA is filed. A basic metabolic panel with creatinine and potassium, UACR, and HbA1c (if diabetic nephropathy is the indication) attached up front reduces delay; missing labs are a common reason for PA holdups.

Step 4. If denied, request the denial in writing. You are entitled to a written denial stating the specific criteria applied. Do not accept a verbal denial alone.

Step 5. File the Level 1 internal appeal within the ACA's 180-day window, using the documentation list above.

Step 6. Consider a cash-pay fill while the appeal is pending. At roughly $10 to $18 per month, continuity of an antihypertensive is usually far safer than a coverage gap. The CDC notes that only about one in four adults with hypertension in the United States has their blood pressure adequately controlled, which is part of why maintaining therapy during a coverage dispute matters. See the CDC's blood pressure facts page.

If the Level 1 appeal is denied, the external IRO review typically must be requested within four months of the final internal denial (confirm the exact deadline on your denial letter, since it can vary by state), and a simultaneous state insurance commissioner complaint can help. Total resolution time varies by how quickly documentation is gathered and how the plan responds; some cases resolve in a few weeks, others take longer.